September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy of a fixed combination of three antibiotics against Candida species
Author Affiliations & Notes
  • Andreana Marino
    Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University, Messina, Italy
  • Valeria D'Angelo
    Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University, Messina, Italy
  • Carmela Giovanna Spoto
    SIFI group, SIFI SpA, Aci S. Antonio, Italy
  • Vincenzo Papa
    SIFI group, SIFI SpA, Aci S. Antonio, Italy
  • Anna Rita Blanco
    SIFI group, SIFI SpA, Aci S. Antonio, Italy
  • Footnotes
    Commercial Relationships   Andreana Marino, None; Valeria D'Angelo, None; Carmela Spoto, SIFI SpA (E); Vincenzo Papa, SIFI SpA (E); Anna Rita Blanco, SIFI SpA (E)
  • Footnotes
    Support   None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Andreana Marino, Valeria D'Angelo, Carmela Giovanna Spoto, Vincenzo Papa, Anna Rita Blanco; Efficacy of a fixed combination of three antibiotics against Candida species. Invest. Ophthalmol. Vis. Sci. 2016;57(12):328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: To evaluate the potential antifungal activity of a commercially available ophthalmic product as fixed antibiotic combination (AC) containing tetracycline, chloramphenicol and colistimethate sodium (Colbiocin, SIFI, Italy), using in vitro and ex vivo models.

Methods : Methods: Candida albicans ATCC 2091 and 10231 and 14 clinical isolates of C. albicans (7), C. glabrata (5), C. utilis (1) and C. tropicalis (1) were used. The MICs of each antibiotic included in the AC were determined either individually or in combination for all strains. Fluconazole was tested for comparison. The Fractional Inhibitory Concentration (FIC) index was also calculated. Time-killing curves for C. albicans ATCC 10231 and for 1 clinical isolate were performed at 10 x MIC values of AC and Fluconazole. Cultured corneal buttons with sclera rims were injected intrastromally with 50 µl of suspension of C. albicans ATCC 10231 containing 5 x 104 colony forming units/ml. Two hours after the injection, corneas were divided into 3 groups of 4 corneas each. The groups were treated with six instillations of AC (first group), Fluconazole (second) or salt solution (third-control) up to 24 h after injection.Then, the tissues were homogenized and plated to determine the number of recovered CFU/g.

Results : Results: MIC values for the individual antibiotics were higher than that observed for Fluconazole. When the AC was used a reduction of the concentration of each antibiotic able to inhibit the yeast growth was observed. In 88% of strains tested the FIC index was between 0.5 and 2.0, indicative of an additive effect. Only in the strains of C. glabrata and C. tropicalis the FIC index was < 0.5 or > 2.0 respectively, indicating a synergic or antagonist effect. The Time-killing curves showed that the AC and Fluconazole, at a concentration 10 x MIC were able to maintain under control the charge for both C. albicans strains up to 10 h (p<0.01 vs. control). After 24 h, the AC reduced of 1 Log the charge compared to the inoculum at the 0 time point. This effect was statistically superior to that of Fluconazole (p<0.001). The AC and Fluconazole were also effective (p<0.01 vs control) in the ex vivo keratitis experiments in decreasing the charge of C. albicans ATCC 10231.

Conclusions :
Conclusions: The ophthalmic AC has a potent antifungal activity and therefore can be effectively used in the treatment of ocular mycotic infections due to Candida species.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×